It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Radioembolization is a valuable therapeutic option in patients with unresectable intrahepatic cholangiocarcinoma. The essential implementation of the absorbed dose calculation methods should take into account also the specific tumor radiosensitivity, expressed by the α parameter. Purpose of this study was to retrospectively calculate it in a series of patients with unresectable intrahepatic cholangiocarcinoma submitted to radioembolization. Twenty-one therapeutic procedures in 15 patients were analysed. Tumor absorbed doses were calculated processing the post-therapeutic 90Y-PET/CT images and the pre-treatment contrast-enhanced CT scans. Tumor absorbed dose and pre- and post-treatment tumor volumes were used to calculate α and α3D parameters (dividing targeted liver in n voxels of the same volume with specific voxel absorbed dose). A tumor volume reduction was observed after treatment. The median of tumor average absorbed dose was 93 Gy (95% CI 81–119) and its correlation with the residual tumor mass was statistically significant. The median of α and α3D parameters was 0.005 Gy−1 (95% CI 0.004–0.008) and 0.007 Gy−1 (95% CI 0.005–0.015), respectively. Multivariate analysis showed tumor volume and tumor absorbed dose as significant predictors of the time to tumor progression. The knowledge of radiobiological parameters gives the possibility to decide the administered activity in order to improve the outcome of the treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Traino Antonio Claudio 2 ; Bargellini Irene 3 ; Lorenzoni Giulia 3 ; Bozzi, Elena 3 ; Vivaldi Caterina 4 ; Lamastra Rocco 2 ; Masi Gianluca 4 ; Cioni, Roberto 3 ; Boni Giuseppe 1 ; Volterrani Duccio 1 1 University Hospital of Pisa, Regional Center of Nuclear Medicine, Pisa, Italy (GRID:grid.144189.1) (ISNI:0000 0004 1756 8209)
2 University Hospital of Pisa, Health Physics Unit, Pisa, Italy (GRID:grid.144189.1) (ISNI:0000 0004 1756 8209)
3 University Hospital of Pisa, Department of Vascular and Interventional Radiology, Pisa, Italy (GRID:grid.144189.1) (ISNI:0000 0004 1756 8209)
4 University Hospital of Pisa, Division of Medical Oncology, Pisa, Italy (GRID:grid.144189.1) (ISNI:0000 0004 1756 8209)




